‘X’ marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma-Reference-Cited by-同舟云学术

‘X’ marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma

Published:2024-07-10 Issue:2 Volume:205 Page:416-417
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Costa Thomaz Alexandre¹^ORCID,Felix Nicole²^ORCID,Richter Joshua³^ORCID

Affiliation:

1. Department of Medicine University of Colorado School of Medicine Aurora Colorado USA

2. Department of Medicine Federal University of Campina Grande Campina Grande Paraíba Brazil

3. Division of Hematology and Medical Oncology Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA

Abstract

Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality among multiple myeloma patients. Chang and colleagues' findings indicate that factor Xa inhibitors are as effective as warfarin in preventing VTE without raising the risk of gastrointestinal or intracranial bleeding complications.Commentary on: Chang et al. The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy. Br J Haematol 2024;205:473‐477.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19640

Reference10 articles.

1. The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy;Chang YC;Br J Haematol,2024

2. National Cancer Institute.SEER Cancer Stat Facts: myeloma.2024.https://seer.cancer.gov/statfacts/html/mulmy.html

3. Multiple myeloma

4. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

5. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma